Mechanisms regulating toxicant disposition to the embryo during early pregnancy: An interspecies comparison

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 72, Issue 4, 2004, Pages 345-360

  Carney, Edward W ^a   Scialli, Anthony R ^b   Watson, Rebecca E ^c   DeSesso, John M ^c  

^a DOW CHEMICAL COMPANY   (United States)

^b Sciences International Inc   (United States)

^c NOBLIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ETHYLENE GLYCOL; GLYCOLIC ACID; PHENOBARBITAL; PHENYTOIN; SALICYLIC ACID; TOXIC SUBSTANCE; VALPROIC ACID;

CHORIOALLANTOIS; EMBRYO DEVELOPMENT; EMBRYO DISPOSITION; EMBRYO TRANSFER; EMBRYOTOXICITY; ENDOCYTOSIS; FETOMATERNAL TRANSFUSION; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HUMAN; MATERNAL BLOOD; NIDATION; NONHUMAN; ORGANOGENESIS; PH; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW; SPECIES COMPARISON; SPECIES DIFFERENCE; TERATOGENICITY; TOXICITY TESTING; UTERUS; YOLK SAC;

ANIMALS; BIOLOGICAL TRANSPORT; CARBAMAZEPINE; EMBRYONIC DEVELOPMENT; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; PHENOBARBITAL; PHENYTOIN; PLACENTA; PREGNANCY; RABBITS; RATS; SALICYLIC ACID; SPECIES SPECIFICITY; TERATOGENS; TOXICITY TESTS; TRETINOIN; VALPROIC ACID; YOLK SAC;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 13444259977     PISSN: 1542975X     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrc.20027     Document Type: Review

References (92)

1. Beck F, Lloyd JB, Griffiths A. 1967. Lysosomal enzyme inhibition by trypan blue: a theory of teratogenesis. Science 157:1180-1182.
2. Beck F. 1976. Comparative placental pathology and function. Environ Health Perspect 18:5-12.
3. Benirschke K. 2004. Comparative placentation. http://medicine.ucsd.edu/ cpa/index.html
4. Bertilsson L. 1978. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet 3:128-143.
5. Brown N. 1987. Teratogenicity of carboxylic acids: distribution studies in whole embryo culture. In : Nau H, Scott WJ Jr, editors. Pharmacokinetics in teratogenesis. Vol. II. Boca Raton: CRC Press, pp. 154-163.
6. Burton GJ, Hempstock J, Jauniaux E. 2001. Nutrition of the human fetus during the first trimester-a review. Placenta 22(Suppl A):S70-S76.
7. Carney EW, Liberacki AB, Tornesi B, et al. 2002. Ethylene glycol kinetics in pregnant rats: differences between slow and fast dose-rate exposures. Toxicologist 66(Suppl 1):139.
8. Christian M, Hoberman A. 1997. Perspectives on the U.S., E.E.C. and Japanese developmental toxicity guidelines. In: Hood R, editor. Handbook of developmental toxicology. Boca Raton: CRC Press. pp. 551-595.
9. Collins MD, Tzimas G, Hummler H, et al. 1994. Comparative teratology and transplacental pharmacokinetics of all-trans-retinoic acid, 13-cis-retinoic acid, and retinyl palmitate following daily administration in rats. Toxicol Appl Pharmacol 127:132-144.
10. Collins MD, Scott WJ Jr, Hendrickx AG, et al. 1996. Intracellular pH of monkey embryos at various stages of organogenesis estimated by dimethadione distribution. Reprod Fertil Dev 8:911-920.
11. Corley RA, Mast TJ, Carney EW, Rogers JM, Daston GP. 2003. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit Rev Toxicol 33:137-211.
12. Creech Kraft J, Kochhar DM, Scott WJ, Nau H. 1987. Low teratogenicity of 13-cis-retinoic acid (isotretinoin) in the mouse corresponds to low embryo concentrations during organogenesis: comparison to the all-trans isomer. Toxicol Appl Pharmacol 87:474-482.
13. Creech Kraft J, Löfberg B, Chahoud I, et al. 1989. Teratogenicity and placental transfer of all-trans-, 13-cis-, 4-oxo-all-trans-, and 4-oxo-13-cis-retinoic acid after administration of a low oral dose during organogenesis in mice. Toxicol Appl Pharmacol 100:162-176.
14. Daston GP, Francis WR, Baines D, et al. 1990. Embryonal disposition of salicylate: in vivo-in vitro comparisons. Teratology 42:225-232.
15. DeCarolis MP, Romagnoli C, Frezza S, et al. 1992. Placental transfer of phenobarbital: what is new? Dev Pharmacol Ther 19:19-26.
16. Dencker L, Danielsson BRG. 1987. Transfer of drugs to the embryo and fetus afterplacentation. In: Nau H, Scott WJ Jr, editors. Pharmacokinetics in #. Vol. I. Boca Raton: CRC Press. pp. 55-70.
17. DeSesso JM, Niewenhuis RJ, Goeringer GC. 1989. Lectin teratogenesis II. Demonstration of increased binding of concanavalin A to limb buds of rabbit embryos during the sensitive period. Teratology 39:395-407.
18. DeSesso JM. 1997. Comparative embryology. In: Hood R, editor. Handbook of developmental toxicology. Boca Raton: CRC Press. pp. 111-174.
19. DeVane CL, Simpkins JW, Stout SA. 1991. Distribution of phenobarbital and phenytoin in pregnant rats and their fetuses. Epilepsia 32:250-256.
20. Dickinson RG, Harland RC, Lynn RK, et al. 1979. Transmission of valproic acid (depakene) across the placenta: half-life of the drug in mother and baby. J Pediatr 94:832-835.
21. Dickinson RG, Fowler DW, Kluck RM. 1989. Maternofetal transfer of phenytoin, p-hydroxy-phenytoin, and p-hydroxy-phenytoin-glucuronide in the perfused human placental. Clin Exp Pharmacol Physiol 16:789-797.
22. Eckhoff C, Bailey JR, Slikker W Jr, Nau H. 1991. Placental transfer of retinoids following high-dose vitamin A during early pregnancy in the monkey. Teratology 43:444.
23. Eckhoff C, Chari S, Kromka M, et al. 1994. Teratogenicity and transplacental pharmacokinetics of 13-cis-retinoic acid in rabbits. Toxicol Appl Pharmacol 125:34-41.
24. Enders AC. 1965. A comparative study of the fine structure in several hemochorial placentas. Am J Anat 116:29-67.
25. Enders AC. 1981. Anatomy of the placenta and its relationship to function. Mead Johnson Symp Perinat Dev Med 18:3-7.
26. Enders AC, Blankenship TN. 1999. Comparative placental structure. Adv Drug Deliv Rev 35:3-15.
27. EPA. 1991. United States Environmental Protection Agency guidelines for developmental toxicity risk assessment. Fed Reg 56:63798-63826.
28. Fenner-Crisp PA, ILSI RSI Human Relevance Work Group. 2004. Using animal and human mode of action information in assessing human risk: a framework for analysis [Abstract]. Toxicologist 78:1801.
29. Finnell RH, Chernoff GF. 1988. Gene-teratogen interactions: an approach to understanding the metabolic basis of birth defects. In: Nau H, Scott WJ Jr, editors. Pharmacokinetics in teratogenesis. Boca Raton: CRC Press. pp. 97-109.
30. Foote RH, Carney EW. 2000. The rabbit as a model for reproductive and developmental toxicity studies. Reprod Toxicol 14:477-493.
31. Fowler DW, Eadie MJ, Dickinson RG. 1989. Transplacental transfer and biotransformation studies of valproic acid and its glucuronide(s) in the perfused human placenta. J Pharmacol Exp Ther 249:318-323.
32. Freeman SJ, Beck F, Lloyd JB. 1981. The role of the visceral yolk sac in mediating protein utilization by rat embryos cultured in vitro. J Embryol Exp Morphol 66:223-234.
33. Garbis-Berkvens JM, Peters PWJ. 1987. Comparative morphology and physiology of embryonic and fetal membranes. In: Nau H, Scott WJ Jr, editors. Pharmacokinetics in teratogenesis. Vol. I. Boca Raton: CRC Press. pp. 13-44.
34. Garrettson LK, Procknal JA, Levy G. 1975. Fetal acquisition and neonatal elimination of a large amount of salicylate. Clin Pharmacol Ther 17:98-103.
35. Gilbert SG. 1989. Pictorial human embryology. Seattle: University of Washington Press. 172 p.
36. Gordon JD, Riggs KW, Rurak DW, et ak. 1995. The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration. Drug Metab Dispos 23:1383-1389.
37. Hamilton WJ, Mossman HW. 1972. Hamilton, Boyd and Mossman's human embryology. 4th ed. Baltimore: Williams and Wilkins Company. 646 p.
38. Hassan-Farghali, Assael BM, Bossi L, Morselli PL. 1975. Placental transfer of carbamazepine in the rat. J Pharm Pharmacol 27:956-957.
39. Hebel R, Stromberg MW. 1986. Anatomy and embryology of the laboratory rat. Worthsee, Germany: BioMed Verlag. 271 p.
40. Holson JF, Stump DG, Pearce LB, et al. 2005. Mode of action: Yolk sac poisoning and impeded histiotrophic nutrition. HBOC-related congenital malformations. Crit Rev Toxicol, in press.
41. Hummler H, Hendrickx AG, Nau H. 1994. Maternal toxicokinetics, metabolism, and embryo exposure following a teratogenic dosing regimen with 13-cis-retinoic acid (isotretinoin) in the cynomolgus monkey. Teratology 50:184-193.
42. Ishizaki T, Yokochi K, Chiba K, et al. 1981. Placental transfer of anticonvulsants (phenobarbital, phenytoin, valproic acid) and the elimination from neonates. Pediatr Pharmacol 1:291-303.
43. Jaffe R, Jauniaux E, Hustin J. 1997. Maternal circulation in the first-trimester human placenta-myth or reality? Am J Obstet Gynecol 176:695-705.
44. Jauniaux E, Gulbis B. 1994. Relationship between protein concentrations in embryological fluids and maternal serum and yolk sac size during human early pregnancy. Hum Reprod 9:161-166.
45. Jauniaux E, Gulbis B. 1997. Embryonal physiology. In: Jauniaux E, Barnea ER, Edwards RG, editors. Embryonic medicine and therapy. Oxford : Oxford University Press. pp. 223-243.
46. Jauniaux E, Gulbis B. 2000. Fluid compartments of the embryonic environment. Hum Reprod 6:268-278.
47. Jollie WP. 1990. Development, morphology, and function of the yolk-sac placenta of laboratory rodents. Teratology 41:361-381.
48. Kaufman P, Burton G. 1994. Anatomy and genesis of the placenta. In: Knobil E, Neill JD, editors. The physiology of reproduction. Vol 1. 2nd ed. New York: Raven Press, Ltd. pp. 441-484.
49. Kimmel CA, Young JF. 1983. Correlating pharmacokinetics and teratogenic end-points. Fundam Appl Toxicol 3:250-255.
50. Kluck RM, Cannell GR, Hooper WD, et al. 1988. Disposition of phenytoin and phenobarbitone in the isolated perfused human placenta. Clin Exp Pharmacol Physiol 15:827-836.
51. Kondo T, Otni K, Hirano T, Kaneko S. 1987. Placental transfer and neonatal elimination of mono-unsaturated metabolites of valproic acid. Br J Clin Pharmacol 24:401-403.
52. Kuemmerle HP. 1974. The diaplacental kinetics of drugs. Int J Clin Pharmacol 9:298-304.
53. Kumar S, Wong H, Yeung SA, et al. 2000a. Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. Drug Metab Dispos 28: 845-856.
54. Kumar S, Wong H, Yeung SA, et al. 2000b. Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination. Drug Metab Dispos 28:857-864.
55. Larsen WJ. 1997. Human embryology. 2nd ed. New York: Churchill Livingstone.
56. Levy G, Procknal JA, Garrettson LK. 1975. Distribution of salicylate between neonatal and maternal serum at diffusion equilibrium. Clin Pharmacol Ther 18:210-214.
57. Löfberg B, Chahoud I, Bochert G, Nau H. 1990. Teratogenicity of 12-cis and all-trans-isomers of the aromatic retinoid etretin: correlation to transplacental pharmacokinetics in mice during organogenesis after a single oral dose. Teratology 41:707-716.
58. Melchior JC, Svensmark O, Trolle D. 1967. Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. Lancet 2:860-861.
59. Mirkin BL. 1971a. Diphenylhydantoin: placental transport, fetal localization, neonatal metabolism, and possible teratogenic effects. Pediatr Pharmacol Ther 78:329-337.
60. Mirkin BL. 1971b. Placental transfer and neonatal elimination of diphenylhydantoin. Am J Obstet Gynecol 109:930-933.
61. Mossman HW. 1937. Comparative morphogenesis of the foetal membranes and accessory uterine structures. Contrib Embryol Carnegie Inst 26:129-246.
62. National Research Council (NRC). 2000. Scientific frontiers in developmental toxicology and risk assessment. Washington: National Academy Press. 327 p.
63. Nau H, Neubert D. 1978. Development of drug metabolizing monooxygenase systems in various mammalian species including man; its significance for transplacental toxicity. In: Neubert D, Merker H-J, Nau H, Langman J, editors. Role of pharmacoliinetics in prenatal and perinatal toxicology. Stuttgart: Georg Thieme Publishers. pp 13-44.
64. Nau H, Rating D, Häuser I, et al. 1980. Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers. Eur J Clin Pharmacol 18:31-42.
65. Nau H, Rating D, Koch S, et al. 1981. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 219: 768-777.
66. Nau H, Kuhnz W, Egger J-J, et al. 1982. Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet 7:508-543.
67. Nau H, Helge H, Luck W. 1984. Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites. J Pediatr 104:627-634.
68. Nau H. 1986. Species differences in pharmacokinetics and drug teratogenesis. Environ Health Perspect 70:113-129.
69. Nau H, Krauer B. 1986. Serum protein binding of valproic acid in fetus-mother pairs throughout pregnancy: correlation with oxytocin administration and albumin and free fatty acid concentrations. J Clin Pharmacol 26:215-221.
70. Nau H, Scott WJ Jr. 1986. Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo. Nature 323:276-278.
71. Neubert D, Siddall RA, Tapken S, et al. 1978. Metabolism of xenobiotics in the fetal and neonatal marmoset monkey (Callithrix jacchus). In: Neubert D, Merker H-J, Nau H, Langman J, editors. Role of pharmacokinetics in prenatal and preinatal toxicology (Third Symposium on Prenatal Development, Berlin). Stuttgart: Georg Thieme Publishers. pp. 299-310.
72. Ninomiya H, Kishida K, Ohno Y, et al. 1993. Effects of trypan blue on rat and rabbit embryos cultured in vitro. Toxicol in Vitro 7:707-717.
73. O'Flaherty EJ. 1994. Physiologically based pharmacokinetic models in developmental toxicology. Risk Anal 14:605-611.
74. O'Flaherty EJ. 1997. Pharmacokinetics, pharmacodynamics, and prediction of developmental abnormalities. Reprod Toxicol 11:413-416.
75. Pelkonen O. 1980. Biotransformation of xenobiotics in the fetus. Pharmacol Ther 10:261.
76. Pienimäki P, Hartikainen A-L, Arvela P, et al. 1995. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 36:241-248.
77. Pitt JA, Carney EW. 1999. Evaluation of various toxicants in rabbit whole-embryo culture using a new morphologicallybased evaluation system. Teratology 59:102-109.
78. Pynnönen S, Kanto J, Sillanpää M, Erkkola R. 1977. Carpamazepine: Placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol 41:244-253.
79. Ramsey EM. 1982. The placenta. New York: Praeger Publishers.
80. Rane A, Bertilsson L, Palmér L. 1975. Disposition of placentally transferred carbamazepine (Tegretol®) in the newborn. Eur J Clin Phamcol 8:283-284.
81. Reynolds SRM. 1972. On growth and form in the hemochorial placenta: an essay on the physical forces that shape the chorionic trophoblast. In: Velardo JT, Kasprow BA, editors. Biology of reproduction: basic and clinical studies. III Pan American Congress of Anatomy. New Orleans. pp. 7-23.
82. Schardein JL, Schwetz BA, Kenel MF. 1985. Species sensitivities and prediction of teratogenic potential. Environ Health Perspect 61:55-67.
83. Schardein JL. 1993. Chemically induced birth defects. New York: Marcel Dekker, Inc.
84. Shah YG, Miller RK. 1985. The pharmacokinetics of phenytoin in perfused human placenta. Pediatr Pharmacol 5:165-179.
85. Shum S, Jensen NM, Nebert DW. 1979. The murine Ah locus; in utero toxicity and teratogenesis associated with genetic differences in benzy(a)pyrene metabolism. Teratology 20:365-376.
86. Srivastava M, Collins MD, Scott WJ Jr, et al. 1991. Transplacental distribution of weak acids in mice: accumulation in compartments of high pH. Teratology 43:325-329.
87. Tornesi B, Carney EW. 2003. Changes in pH gradients, protein and osmolarity of the rabbit conceptus during gestation (GD) 9-12. Birth Defects Res Part B Dev Reprod Toxicol 68:262.
88. Tzimas G, Bürgin H, Collins MD, et al. 1994. The high sensitivity of the rabbit to the teratogenic effects of 13-cis-retinoic acid (isotretinoin) is a consequence of prolonged exposure of the embryo to 13-cis-retinoic acid and 13-cis-4-oxo-retinoic acid, and not of isomerization to all-trans-retinoic acid. Arch Toxicol 68:119-128.
89. Tzimas G, Collins MD, Nau H. 1995. Developmental stage-associated differences in the transplacental distribution of 13-cis- and all-trans-retinoic acid as well as their glucuronides in rats and mice. Toxicol Appl Pharmacol 133:91-101.
90. Varma DR. 1988. Modification of transplacental distribution of salicylate in rats by acidosis and alkalosis. Br J Pharmacol 93:978-984.
91. Wells MY, Decobecq C P-M, Decouvelaere DM, et al. 1999. Changes in clinical pathology parameters during gestation in the New Zealand White rabbit. Toxicol Pathol 27:370-379.
92. Wilson JG. 1971. Use of rhesus monkeys in teratological studies. Fed Proc 30:104-109.